If you’re searching for what is actually happening in the U.S. economy in 2026, the honest answer isn’t hidden in a data release. It’s hidden in behavior. The economy is functioning.But it doesn’t trust itself. That single fact explains why so many headlines feel disconnected from lived reality — and why FP&A teams, finance leaders, […]
A Counterintuitive Start Finance has always been seen as the function of “no.” No to risk. No to expansion. No to ideas that didn’t fit the spreadsheet. But what if finance wasn’t about rejection at all? That’s the paradox Sarah Schlott leans into. For her, finance is not a brake pedal — it’s a navigation […]
Jaguar Land Rover cyberattack halts production Jaguar Land Rover has extended its production shutdown until at least October 1, 2025, following a crippling cyberattack that disrupted core operations across its U.K. factories. What began as a short pause has stretched into weeks of halted assembly lines, idle workers, and suppliers under stress. The company […]
Why automakers and FP&A teams must brace for a post-incentive world. A Subsidy Built Into the Price Tag For 16 years, U.S. buyers of electric vehicles counted on a cushion: the $7,500 federal tax credit. It narrowed the affordability gap. It signaled government commitment. And it gave automakers cover while they scaled production and reduced […]
Why FP&A Must Treat Geopolitics as a Financial Driver North Korea set new conditions for resuming talks with the United States, with Kim Jong Un citing his “fond memories” of meetings with Donald Trump but insisting Washington drop demands for denuclearisation. The headline may sound like pure politics. But to financial planning and analysis (FP&A) […]
Why FP&A Must Model Policy Shock Like Market Shock Indian IT shares dropped sharply after reports that the U.S. may introduce a $100,000 H-1B visa application fee, a move tied to proposals from former President Donald Trump’s campaign. The change could hit a $283 billion Indian IT services industry, heavily reliant on H-1B visas to […]
Why Pfizer’s Metsera Buyout Is a Lesson in FP&A Agility Pfizer Inc. is closing in on a $7.3 billion acquisition of Metsera, an anti-obesity drugmaker. If finalized, it would be one of the largest pharma M&A deals in years — and Pfizer’s boldest attempt to diversify as COVID-19 vaccine revenue falls. The prize? Entry into […]